Sarepta Therapeutics (SRPT) Tops Q3 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments
November 7, 2019 4:07 PM ESTCAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2019.
EXONDYS 51® (eteplirsen) enjoyed another strong quarter, with third quarter 2019 revenues of $99.0 million, a 26% increase over the same quarter in 2018.  Based on current performance, we have raised our full-year 2019 guidance from a range of $365 to $375 million to $370 to $380 million, stated Doug Ingram, Sareptas President and CEO.
Mr. Ingram continued, We have also made significant progress advancing... More
